PremiumCompany AnnouncementsPassage Bio Reports Q1 2025 Financial Results and Updates Passage Bio reports Q1 EPS (25c), consensus (22c) Passage Bio Advances Gene Therapy for Neurodegenerative Diseases PremiumThe FlyPassage Bio reports FY24 EPS ($1.07) vs ($1.86) last year Passage Bio announces data from upliFT-D study in FTD-GRN, provides update Passage Bio Restructures and Extends Cash Runway PremiumPre-EarningsPASG Upcoming Earnings Report: What to Expect? Passage Bio Presents Promising Data on PBFT02 Therapy Passage Bio delivered preclinical, interim data at ESGCT 
